User contributions for Alara E. Dagsali

Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽
(newest | oldest) View (newer 20 | ) (20 | 50 | 100 | 250 | 500)

30 April 2024

  • 18:5818:58, 30 April 2024 diff hist +20‎ User:AED ‎No edit summary current
  • 18:5818:58, 30 April 2024 diff hist +3‎ Isosulfan Blue ‎No edit summary current
  • 18:5718:57, 30 April 2024 diff hist +5,959‎ N Isosulfan Blue ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape..."
  • 18:4718:47, 30 April 2024 diff hist +22‎ User:AED ‎No edit summary
  • 18:4718:47, 30 April 2024 diff hist +3‎ Ibuprofen Lysine ‎No edit summary current
  • 18:4618:46, 30 April 2024 diff hist +15,663‎ N Ibuprofen Lysine ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc..."
  • 18:2818:28, 30 April 2024 diff hist +20‎ User:AED ‎No edit summary
  • 18:2818:28, 30 April 2024 diff hist +3‎ Prussian blue ‎No edit summary current
  • 18:2718:27, 30 April 2024 diff hist +14,067‎ N Prussian blue ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R..."
  • 18:1518:15, 30 April 2024 diff hist +23‎ User:AED ‎No edit summary
  • 18:1518:15, 30 April 2024 diff hist +3‎ Botulism Antitoxin ‎No edit summary current
  • 18:1418:14, 30 April 2024 diff hist +18,008‎ N Botulism Antitoxin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse..."

29 April 2024

  • 15:2615:26, 29 April 2024 diff hist +27‎ User:AED ‎No edit summary
  • 15:2515:25, 29 April 2024 diff hist −35‎ Trastuzumab emtansine ‎No edit summary current
  • 15:2315:23, 29 April 2024 diff hist +40,610‎ N Trastuzumab emtansine ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment..."

25 April 2024

(newest | oldest) View (newer 20 | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://www.wikidoc.org/index.php/Special:Contributions/Alara_E._Dagsali"